Oligonucleotide for inducing N-exon skipping during rest mRNA precursor processing
AssigneeOsaka University
InventorsMasahito Shimojo, Satoshi Obika, Keishiro Mishima, Misa Yoshida
Life of this patent
Estimating the term…
Abstract
An oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region constituted by a base sequence of SEQ ID No. 1, and induces N-exon skipping in human REST pre-mRNA processing. Such oligonucleotides are useful for manufacturing medicines for treatment of cancer, for example.
Claims9
An oligonucleotide or a pharmacologically acceptable salt thereof comprising a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region consisting of a base sequence of SEQ ID No. 1;
- wherein the oligonucleotide or pharmacologically acceptable salt thereof induces N-exon skipping in human RE1-silencing transcription factor (REST) pre-mRNA processing, and
- wherein the oligonucleotide has a length of 12 to 35 bases.
Dependencies are inferred from the claim text.